PYC Therapeutics (ASX:PYC) said that a safety review committee governing the phase 1a/1b study confirmed that single doses of its PYC-003 drug candidate, for the treatment of the underlying causes of polycystic kidney disease, up to and including 4 milligram-per-kilogram in healthy volunteers, were considered to be safe and well tolerated, according to a Friday Australian bourse filing.

The committee governing the single ascending dose clinical trial reviewed the four-week safety data from all four groups of healthy volunteers enrolled in part A of the study.

The study seeks to evaluate the safety/tolerability profile of the drug candidate, with a secondary objective to evaluate the efficacy of the drug candidate in polycystic kidney disease patients.

The firm does not plan to escalate dosing in healthy volunteers further.

Its shares rose 1% in recent trading on Friday.